Overview

* CASI Q3 revenue falls 60% yr/yr due to estimated goods returns for EVOMELA

* Net loss for Q3 2025 increased to $10.9 mln from $8.4 mln last year

* Company appeals Nasdaq delisting determination, seeking extension to regain compliance

Outlook

* CASI plans to complete China business divestiture by Q2 2026

* Company to present CID-103 study results at ASH 2025 on Dec 7

* CASI advancing CID-103 trials in U.S. and China

Result Drivers

* REVENUE DECLINE - Revenue fell 60% yr/yr due to estimated goods returns for EVOMELA, which also impacted net loss

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $3.08

Revenue mln

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for CASI Pharmaceuticals Inc ( CASI ) is $4.00, about 66.6% above its November 13 closing price of $1.34

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)